HEPATOCELLULAR CARCINOMA (HCC)

This study is testing an experimental drug called BB102 for people with advanced liver cancer that has a specific genetic feature (FGF19 overexpression) and has stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and control the disease. Ab…

This study is testing two oral medications, lenvatinib and regorafenib, for people with advanced liver cancer that has continued to grow despite initial immunotherapy treatment. Researchers want to see if these drugs can slow cancer progression and extend life for patients with d…

This study is testing a procedure called irreversible electroporation (IRE) to destroy small liver tumors in patients with early-stage liver cancer and good liver function. The procedure uses electrical pulses to kill cancer cells without using heat. Researchers will track how we…

This study is testing a combination of four treatments for advanced liver cancer that cannot be removed by surgery. It aims to see if adding a new drug (ipilimumab N01) to a standard three-part regimen is safe and more effective. Researchers will enroll 36 adults and compare thre…

This study aims to find out if a precise, non-surgical radiation treatment is as good as or better than surgery for people with a single, small liver tumor. It will compare survival rates and side effects between the two approaches. The goal is to provide high-quality evidence to…

This study compares a new combination treatment (SH006 injection plus other cancer drugs) against an existing medication (regorafenib) for advanced liver cancer. It's for patients whose cancer continued to grow despite previous immunotherapy treatment. Researchers want to see if …

This study aims to find out if using two antiviral drugs together works better than using one drug alone for people with advanced liver cancer caused by hepatitis B. Researchers will compare how long 120 patients live after starting cancer immunotherapy, depending on which antivi…

This study is for adults with advanced liver cancer (HCC) that has worsened after their first immunotherapy treatment. It will test if adding a new, liver-targeted oral drug called fostrox to the standard drug lenvatinib is more effective and safe than using lenvatinib alone. Abo…

This study is testing a combination treatment for liver cancer that has grown too much for standard surgery. Patients will receive a targeted chemotherapy procedure (TACE) plus an immunotherapy drug (QL1706) before their tumor is removed, and then continue the immunotherapy after…

This study aims to see if adding a targeted liver chemotherapy infusion (HAIC) to a standard two-drug regimen (lenvatinib and a PD-1 inhibitor) works better for people with advanced liver cancer that has grown into major blood vessels or bile ducts. It will enroll 150 patients wh…

This study is testing whether a combination of two immunotherapy drugs, IBI310 and sintilimab, can help people with advanced liver cancer that cannot be removed by surgery. It will involve about 680 adults who have not yet received any drug treatment for their cancer. The main go…

This study tests whether computer software that shows doctors exactly what part of a liver tumor has been treated during a microwave ablation procedure helps them completely destroy the cancer. Researchers will compare results using this guidance software against past treatments …

This study is testing whether adding a traditional Chinese herbal formula called Fufang Biejiaruangan to standard antiviral treatment can help prevent liver cancer in people with hepatitis B-related cirrhosis. Researchers will enroll over 1,000 patients at high risk for cancer an…

This early-phase study is testing a new type of cell therapy called Meta10-GPC3 CAR-T in patients with advanced liver cancer that has returned or spread and cannot be surgically removed. The main goals are to see if the treatment is safe and to look for early signs that it can sh…

This study is testing a personalized treatment approach for advanced liver cancer that cannot be removed by surgery. Doctors will analyze each patient's tumor to classify its metabolism and then assign a tailored combination of immunotherapy and other treatments. The goal is to s…

This study aims to see if adding a new oral drug, TPST-1120, to the current standard treatment helps adults with advanced liver cancer live longer and keep their cancer from growing. About 740 participants will be randomly assigned to receive either the new three-drug combination…

This study is testing a three-part treatment for a severe form of liver cancer that has spread into a major vein, making patients ineligible for surgery. The goal is to see if combining chemotherapy delivered directly to the liver, a targeted pill, and an immunotherapy drug can s…

This study is for people with advanced liver cancer whose initial immunotherapy treatment has stopped working. It tests whether adding a fecal microbiota transplant (FMT) and a specialized form of radiation to the original treatment can help control the cancer better than simply …

This study is testing a three-part treatment for liver cancer that is difficult to remove with surgery alone. First, patients receive two immunotherapy drugs (nivolumab and ipilimumab) and targeted radiation (SBRT) to try to shrink the tumor. If the tumor shrinks enough, surgeons…

This study is testing a new combination of treatments for advanced liver cancer (hepatocellular carcinoma). It will give 41 participants a mix of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706), a targeted drug (lenvatinib), and a localized procedur…

This study is testing the drug cabozantinib for people with advanced liver cancer (hepatocellular carcinoma) whose disease has gotten worse after standard first-line immunotherapy combinations. The main goals are to see if the drug can control the cancer for at least 6 months and…

This study is testing if ondansetron, a medicine often used for nausea, can help reduce the harmful side effects caused by powerful immunotherapy drugs used to treat liver cancer. It will involve 66 patients who are scheduled to receive standard immunotherapy. Researchers will co…

This study is testing a new blood test to see if it can accurately tell when liver cancer returns after a patient's initial treatment. Researchers will enroll 162 adults who have had or will have treatment like surgery or ablation. They will compare the results of this new test a…

This study is testing a new way to check if a liver cancer radiation treatment called radioembolization is safe for a patient's lungs. Researchers will compare a new 'scout dose' method using the actual treatment beads against the current standard test in 30 patients with liver t…

This study is developing an artificial intelligence (AI) tool to help doctors choose the best treatment for patients after liver cancer surgery. The AI analyzes standard digital images of a patient's tumor tissue to predict whether they are likely to benefit from specific follow-…

This study aims to find out if specific substances in the blood can predict how well patients with liver cancer will respond to a standard treatment called chemoembolization (TACE). Researchers will follow 60 patients receiving this standard care, taking blood samples before and …

This study aims to see if a more detailed 3D measurement from CT scans can better show how well treatments are working for liver cancer. It will involve 66 adults with liver cancer who are not eligible for surgery and are receiving specific non-surgical treatments. The goal is to…

This study aims to understand why liver cancer patients have different outcomes and side effects when receiving a combination of localized and drug-based treatments. Researchers will analyze real-world medical records from 2,000 patients to identify patterns. The goal is to build…